114 related articles for article (PubMed ID: 16634342)
1. Evaluating rehabilitation using cost-consequences analysis: an example in Parkinson's disease.
Gage H; Kaye J; Owen C; Trend P; Wade D
Clin Rehabil; 2006 Mar; 20(3):232-8. PubMed ID: 16634342
[TBL] [Abstract][Full Text] [Related]
2. Short-term effectiveness of intensive multidisciplinary rehabilitation for people with Parkinson's disease and their carers.
Trend P; Kaye J; Gage H; Owen C; Wade D
Clin Rehabil; 2002 Nov; 16(7):717-25. PubMed ID: 12428820
[TBL] [Abstract][Full Text] [Related]
3. Multidisciplinary rehabilitation for people with Parkinson's disease: a randomised controlled study.
Wade DT; Gage H; Owen C; Trend P; Grossmith C; Kaye J
J Neurol Neurosurg Psychiatry; 2003 Feb; 74(2):158-62. PubMed ID: 12531939
[TBL] [Abstract][Full Text] [Related]
4. A comparison of specialist rehabilitation and care assistant support with specialist rehabilitation alone and usual care for people with Parkinson's living in the community: study protocol for a randomised controlled trial.
Gage H; Ting S; Williams P; Bryan K; Kaye J; Castleton B; Trend P; Wade D
Trials; 2011 Nov; 12():250. PubMed ID: 22112960
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of occupational therapy in Parkinson's disease: A randomized controlled trial.
Sturkenboom IH; Hendriks JC; Graff MJ; Adang EM; Munneke M; Nijhuis-van der Sanden MW; Bloem BR
Mov Disord; 2015 Jul; 30(8):1059-67. PubMed ID: 25854809
[TBL] [Abstract][Full Text] [Related]
6. Economic and health-related quality of life considerations of new therapies in Parkinson's disease.
Rubenstein LM; DeLeo A; Chrischilles EA
Pharmacoeconomics; 2001; 19(7):729-52. PubMed ID: 11548910
[TBL] [Abstract][Full Text] [Related]
7. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
Allen D; Rixson L
Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
[TBL] [Abstract][Full Text] [Related]
8. A review of the health-related quality of life and economic impact of Parkinson's disease.
Dowding CH; Shenton CL; Salek SS
Drugs Aging; 2006; 23(9):693-721. PubMed ID: 17020395
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of day and inpatient psychiatric treatment: results of a randomised controlled trial.
Creed F; Mbaya P; Lancashire S; Tomenson B; Williams B; Holme S
BMJ; 1997 May; 314(7091):1381-5. PubMed ID: 9161310
[TBL] [Abstract][Full Text] [Related]
10. Integrated multidisciplinary care in Parkinson's disease: a non-randomised, controlled trial (IMPACT).
van der Marck MA; Munneke M; Mulleners W; Hoogerwaard EM; Borm GF; Overeem S; Bloem BR;
Lancet Neurol; 2013 Oct; 12(10):947-56. PubMed ID: 23988337
[TBL] [Abstract][Full Text] [Related]
11. Rehabilitation for Parkinson's disease: a systematic review of available evidence.
Gage H; Storey L
Clin Rehabil; 2004 Aug; 18(5):463-82. PubMed ID: 15293481
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the role of the Parkinson's disease nurse specialist.
Reynolds H; Wilson-Barnett J; Richardson G
Int J Nurs Stud; 2000 Aug; 37(4):337-49. PubMed ID: 10760541
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a nurse-led multidisciplinary neurological rehabilitation programme using the Nottingham Health Profile.
Sitzia J; Haddrell V; Rice-Oxley M
Clin Rehabil; 1998 Oct; 12(5):389-94. PubMed ID: 9796929
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of 40-hour versus 100-hour vocational rehabilitation on work participation for workers on sick leave due to subacute or chronic musculoskeletal pain: study protocol for a randomized controlled trial.
Beemster TT; van Velzen JM; van Bennekom CA; Frings-Dresen MH; Reneman MF
Trials; 2015 Jul; 16():317. PubMed ID: 26215748
[TBL] [Abstract][Full Text] [Related]
15. Estimating the direct and indirect costs associated with Parkinson's disease.
Rodríguez-Blázquez C; Forjaz MJ; Lizán L; Paz S; Martínez-Martín P
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):889-911. PubMed ID: 26511768
[TBL] [Abstract][Full Text] [Related]
16. An economic model of Parkinson's disease: implications for slowing progression in the United States.
Johnson SJ; Diener MD; Kaltenboeck A; Birnbaum HG; Siderowf AD
Mov Disord; 2013 Mar; 28(3):319-26. PubMed ID: 23404374
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of a geriatric rehabilitation programme: a randomized controlled trial.
Kehusmaa S; Autti-Rämö I; Valaste M; Hinkka K; Rissanen P
J Rehabil Med; 2010 Nov; 42(10):949-55. PubMed ID: 21031292
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.
Nuijten MJ; van Iperen P; Palmer C; van Hilten BJ; Snyder E
Value Health; 2001; 4(4):316-28. PubMed ID: 11705299
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of a three-month exercise programme vs usual care following multidisciplinary rehabilitation for chronic low back pain.
Henchoz Y; Pinget C; Wasserfallen JB; Paillex R; de Goumoëns P; Norberg M; Kai-Lik So A
J Rehabil Med; 2010 Oct; 42(9):846-52. PubMed ID: 20878045
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
